Rentschler Invests in New Stainless-Steel Bioreactors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rentschler Invests in New Stainless-Steel Bioreactors


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 7

Rentschler Biotechnologie GmbH, a CMO for the development and production of biopharmaceuticals, reported the investment of €24 million (approximately $32 million) to build a twin system with two 3000-L stainless-steel bioreactors mainly targeting market supply at the company’s site in Laupheim, Germany. The twin system should be operational in early 2017.

The twin system is designed for running two main bioreactors in parallel with one shared downstream processing unit, thus providing higher throughput while reducing incremental labor costs involved. It will be integrated into the existing 3000-L GMP line and will more than double the production capacities for cell culture-derived proteins. The twin system will allow Rentschler to run cell-culture processes in fed-batch mode with a high output in a single suite.

Source:Rentschler Biotechnologie GmbH

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here